133 related articles for article (PubMed ID: 25200358)
1. The incidence of radioepidermitis and the dose-response relationship in parotid gland cancer patients treated with 125I seed brachytherapy: incidence of radioepidermitis and the dose-response relationship.
Mao MH; Zhang JG; Zheng L; Gao H; Zhang J; Liu SM; Huang MW; Shi Y
Strahlenther Onkol; 2015 Jan; 191(1):26-33. PubMed ID: 25200358
[TBL] [Abstract][Full Text] [Related]
2. Surgery combined with postoperative
Mao MH; Zheng L; Wang XM; Li H; Qin LZ; Zhang J; Han ZX; Zhang JG
Pediatr Blood Cancer; 2017 Jan; 64(1):57-63. PubMed ID: 27576792
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of (125)I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients.
Zheng L; Zhang J; Zhang J; Song T; Huang M; Yu G
Head Neck; 2012 Oct; 34(10):1445-9. PubMed ID: 22488812
[TBL] [Abstract][Full Text] [Related]
4. 125I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents.
Zheng L; Zhang J; Song T; Zhang J; Yu G; Zhang Y
Strahlenther Onkol; 2013 May; 189(5):401-6. PubMed ID: 23519359
[TBL] [Abstract][Full Text] [Related]
5. Postoperative [¹²⁵I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland: with associated risk factors.
Mao MH; Zhang JG; Zhang J; Zheng L; Liu SM; Huang MW; Shi Y
Strahlenther Onkol; 2014 Oct; 190(11):1008-14. PubMed ID: 24781865
[TBL] [Abstract][Full Text] [Related]
6. Brachytherapy for recurrent malignant tumours of the parotid gland.
Zhang J; Zheng L; Liu SM; Huang MW; Shi Y; Wang W; Zhang JG
Br J Oral Maxillofac Surg; 2015 Jan; 53(1):58-62. PubMed ID: 25445387
[TBL] [Abstract][Full Text] [Related]
7. 125I seed implant brachytherapy-assisted surgery with preservation of the facial nerve for treatment of malignant parotid gland tumors.
Zhang J; Zhang JG; Song TL; Zhen L; Zhang Y; Zhang KH; Yang ZH; Yu GY
Int J Oral Maxillofac Surg; 2008 Jun; 37(6):515-20. PubMed ID: 18508237
[TBL] [Abstract][Full Text] [Related]
8. Three-Dimensional Printed Plate-Guided
Liu J; Wu T; Man Q; Fidèle NB; Zheng Y; Liu B
J Oral Maxillofac Surg; 2018 Oct; 76(10):2113-2121. PubMed ID: 29856941
[TBL] [Abstract][Full Text] [Related]
9. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
[TBL] [Abstract][Full Text] [Related]
10. Rectal dosimetric analysis following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Walbert HL; Blatt HJ
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1021-7. PubMed ID: 10192350
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary study of treating parotid gland malignant tumor with saving facial nerve (surgery associated with 125I seed implant brachytherapy)].
Zhanf JG; Zhang J; Song TL; Zheng L; Cai ZG; Yu GY
Zhonghua Kou Qiang Yi Xue Za Zhi; 2008 Mar; 43(3):132-5. PubMed ID: 18788543
[TBL] [Abstract][Full Text] [Related]
12. Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation.
Brown D; Colonias A; Miller R; Benoit R; Cohen J; Arshoun Y; Galloway M; Karlovits S; Wu A; Johnson M; Quinn A; Kalnicki S
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):353-60. PubMed ID: 10802359
[TBL] [Abstract][Full Text] [Related]
13. Probability of late rectal morbidity in 125I prostate brachytherapy.
Waterman FM; Dicker AP
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):342-53. PubMed ID: 12527047
[TBL] [Abstract][Full Text] [Related]
14. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
15. The role of
Huang MW; Wu WJ; Lv XM; Yu GY; Zhang JG
Brachytherapy; 2018; 17(1):244-249. PubMed ID: 29102739
[TBL] [Abstract][Full Text] [Related]
16. Iodine-125 brachytherapy alone for advanced primary parotid gland carcinoma.
Zhou C; Zhang J; Zhang JG; Liu SM; Zheng L; Huang MW; Shi Y; Lv XM
Int J Oral Maxillofac Surg; 2018 May; 47(5):561-567. PubMed ID: 28966067
[TBL] [Abstract][Full Text] [Related]
17. [125I seed implant brachytherapy of recurrent parotid gland malignant tumor].
Zhang J; Zhang JG; Cai ZG; Zhang Y; Huang MX; Yu GY
Zhonghua Kou Qiang Yi Xue Za Zhi; 2009 Jan; 44(1):2-4. PubMed ID: 19489249
[TBL] [Abstract][Full Text] [Related]
18. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?
Stone NN; Cesaretti JA; Rosenstein B; Stock RG
Brachytherapy; 2010; 9(2):114-8. PubMed ID: 19879812
[TBL] [Abstract][Full Text] [Related]
19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
20. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.
Snyder KM; Stock RG; Hong SM; Lo YC; Stone NN
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):335-41. PubMed ID: 11380219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
